D. Oh, A. Ruth He, S. Qin, Li‐Tzong Chen, T. Okusaka, A. Vogel, J. W. Kim, T. Suksombooncharoen, Myung Ah Lee, Masayuki Kitano, H. Burris, Mohamed Bouattour, S. Tanasanvimon, M. McNamara, R. Zaucha, A. Avallone, Benjamin Tan, Juan Cundom, Choong-kun Lee, Hidenori Takahashi, M. Ikeda, Jen‐Shi Chen, Julie Wang, M. Makowsky, N. Rokutanda, P. He, J. Kurland, G. Cohen, J. Valle
2022.6.1NEJM Evidence
tlooto Summary
Patients with previously untreated locally advanced or metastatic biliary tract cancer to receive durvalumab or placebo in combination with gemcitabine plus cisplatin received durvalumab or placebo in combination with gemcitabine plus cisplatin.
Abstract
Durvalumab Combination for Biliary Tract CancerThis trial randomly assigned patients with previously untreated locally advanced or metastatic biliary tract cancer to receive durvalumab or placebo in combination with gemcitabine plus cisplatin. Median overall survival (95% Cl) was 12.8 (11.1-14.0) months in the durvalumab group. Rates of grade 3 or 4 adverse events were similar between groups.
Citation format
OH, D., et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evidence, 2022, 1 8: EVIDoa2200015.